Our proprietary Gemini Digital Twin (GDT) platform builds computational representations of human disease that comprehensively capture the genetic and molecular interactions that drive clinical and physiological outcomes.
Deriving insights from human datasets; by starting with human multiomic and clinical data, Aitia eliminates the need to use insufficient and often irrelevant model systems (e.g., cell lines, animal models) that are poor predictors of human biology and clinical outcomes
Identifying targets causally linked to clinical outcomes decades before anyone else; Aitia runs counter factual “in silico” experiments testing hypotheses across our Gemini Digital Twin platform-derived models built from human patient data
Discovering targets at a speed and scale that is not possible from high-throughput experiments or other platforms; Aitia evaluates the impact of trillions of parameters on clinical outcomes in each of trillions of simulations
Simulating drug candidates and clinical trials to discover biomarkers of response / non-response and optimal combo therapies early in development
